Published in Biomaterials on May 02, 2006
Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater (2009) 11.95
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. Part Fibre Toxicol (2012) 1.87
Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy. ACS Nano (2010) 1.82
Engineering nano- and microparticles to tune immunity. Adv Mater (2012) 1.75
Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond) (2010) 1.51
A stimulus-responsive contrast agent for ultrasound molecular imaging. Biomaterials (2007) 1.22
Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther (2012) 1.18
Characterization of different functionalized lipidic nanocapsules as potential drug carriers. Int J Mol Sci (2012) 1.14
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev (2015) 1.08
Nanoparticle characterization: state of the art, challenges, and emerging technologies. Mol Pharm (2013) 1.04
Unambiguous observation of shape effects on cellular fate of nanoparticles. Sci Rep (2014) 1.00
Injectable PLGA based colloidal gels for zero-order dexamethasone release in cranial defects. Biomaterials (2010) 1.00
Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv (2013) 0.99
Synthesis and in vivo pharmacokinetic evaluation of degradable shell cross-linked polymer nanoparticles with poly(carboxybetaine) versus poly(ethylene glycol) surface-grafted coatings. ACS Nano (2012) 0.97
Concepts and practices used to develop functional PLGA-based nanoparticulate systems. Int J Nanomedicine (2013) 0.97
Preparation and in vitro characterization of 9-nitrocamptothecin-loaded long circulating nanoparticles for delivery in cancer patients. Int J Nanomedicine (2010) 0.93
Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. Angew Chem Int Ed Engl (2012) 0.91
Optimization of PEGylation conditions for BSA nanoparticles using response surface methodology. AAPS PharmSciTech (2010) 0.91
Exploiting endocytosis for nanomedicines. Cold Spring Harb Perspect Biol (2013) 0.89
Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. Biomaterials (2014) 0.89
Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.88
Effect of surface architecture on in vivo ultrasound contrast persistence of targeted size-selected microbubbles. Ultrasound Med Biol (2012) 0.88
Umbilical cord mesenchymal stem cells labeled with multimodal iron oxide nanoparticles with fluorescent and magnetic properties: application for in vivo cell tracking. Int J Nanomedicine (2014) 0.87
Polymeric micelles of PEG-PE as carriers of all-trans retinoic acid for stability improvement. AAPS PharmSciTech (2012) 0.86
Increased osteoblast functions in the presence of BMP-7 short peptides for nanostructured biomaterial applications. J Biomed Mater Res A (2009) 0.85
Design of siRNA Therapeutics from the Molecular Scale. Pharmaceuticals (Basel) (2013) 0.84
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev (2016) 0.84
Bacterial Magnetosome: A Novel Biogenetic Magnetic Targeted Drug Carrier with Potential Multifunctions. J Nanomater (2011) 0.83
The use of convection-enhanced delivery with liposomal toxins in neurooncology. Toxins (Basel) (2011) 0.83
Preliminary biocompatibility investigation of magnetic albumin nanosphere designed as a potential versatile drug delivery system. Int J Nanomedicine (2011) 0.83
Novel drug delivery system based on docetaxel-loaded nanocapsules as a therapeutic strategy against breast cancer cells. Int J Mol Sci (2012) 0.83
Zwitterionic poly(amino acid methacrylate) brushes. J Am Chem Soc (2014) 0.83
Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle. J Control Release (2015) 0.82
Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice. Nanomedicine (2014) 0.81
Nanoparticle mediated drug delivery of rolipram to tyrosine kinase B positive cells in the inner ear with targeting peptides and agonistic antibodies. Front Aging Neurosci (2015) 0.81
Translocation of PEGylated quantum dots across rat alveolar epithelial cell monolayers. Int J Nanomedicine (2011) 0.81
Nanoparticle targeting to diseased vasculature for imaging and therapy. Nanomedicine (2014) 0.81
Photocytotoxicity of mTHPC (temoporfin) loaded polymeric micelles mediated by lipase catalyzed degradation. Pharm Res (2008) 0.80
Biomaterial Strategies for Immunomodulation. Annu Rev Biomed Eng (2015) 0.79
Sensing surface PEGylation with microcantilevers. Beilstein J Nanotechnol (2010) 0.79
Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy. J Control Release (2015) 0.79
Peptide amphiphile containing arginine and fatty acyl chains as molecular transporters. Mol Pharm (2013) 0.79
Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis. Adv Healthc Mater (2015) 0.78
TUNABLE COMPLEMENT ACTIVATION BY PARTICLES WITH VARIABLE SIZE AND Fc DENSITY. Nano Life (2013) 0.78
Safety of poly (ethylene glycol)-coated perfluorodecalin-filled poly (lactide-co-glycolide) microcapsules following intravenous administration of high amounts in rats. Results Pharma Sci (2014) 0.78
PEG-b-AGE Polymer Coated Magnetic Nanoparticle Probes with Facile Functionalization and Anti-fouling Properties for Reducing Non-specific Uptake and Improving Biomarker Targeting. J Mater Chem B Mater Biol Med (2015) 0.78
PEGylated graphene oxide elicits strong immunological responses despite surface passivation. Nat Commun (2017) 0.78
Ultrasensitive detection of proteins on Western blots with semiconducting polymer dots. Macromol Rapid Commun (2013) 0.77
Preparation and characterization of ketoprofen-loaded microspheres for embolization. J Mater Sci Mater Med (2011) 0.77
Nanotechnology for protein delivery: Overview and perspectives. J Control Release (2015) 0.77
Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers. Pharm Res (2009) 0.77
Barriers to inhaled gene therapy of obstructive lung diseases: A review. J Control Release (2016) 0.77
Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(α-Glutamic Acid) complex. Antimicrob Agents Chemother (2013) 0.77
A review of solute encapsulating nanoparticles used as delivery systems with emphasis on branched amphipathic peptide capsules. Arch Biochem Biophys (2016) 0.77
Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks. AAPS J (2014) 0.76
Nanoemulsion loaded with lycobetaine-oleic acid ionic complex: physicochemical characteristics, in vitro, in vivo evaluation, and antitumor activity. Int J Nanomedicine (2013) 0.76
Single-Step Assembly of Multimodal Imaging Nanocarriers: MRI and Long-Wavelength Fluorescence Imaging. Adv Healthc Mater (2015) 0.76
Developments in the use of nanocapsules in oncology. Braz J Med Biol Res (2013) 0.76
Mithramycin encapsulated in polymeric micelles by microfluidic technology as novel therapeutic protocol for beta-thalassemia. Int J Nanomedicine (2012) 0.75
Biodistribution and fate of core-labeled (125)I polymeric nanocarriers prepared by Flash NanoPrecipitation (FNP). J Mater Chem B Mater Biol Med (2016) 0.75
Allergic Responses Induced by the Immunomodulatory Effects of Nanomaterials upon Skin Exposure. Front Immunol (2017) 0.75
The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate. Int J Nanomedicine (2016) 0.75
Effect of the excipient concentration on the pharmacokinetics of PM181104, a novel antimicrobial thiazolyl cyclic peptide antibiotic, following intravenous administration to mice. Results Pharma Sci (2014) 0.75
Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells. J Nanobiotechnology (2014) 0.75
Evaluation of the efficiency of tumor and tissue delivery of carrier-mediated agents (CMA) and small molecule (SM) agents in mice using a novel pharmacokinetic (PK) metric: relative distribution index over time (RDI-OT). J Nanopart Res (2014) 0.75
Penetration of CdSe/ZnS quantum dots into differentiated vs undifferentiated Caco-2 cells. J Nanobiotechnology (2016) 0.75
Surfactant-free colloidal particles with specific binding affinity. Langmuir (2017) 0.75
Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes. Int J Pharm (2017) 0.75
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials (2008) 2.43
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood (2007) 1.83
Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release (2008) 1.82
Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Release (2006) 1.76
Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res (2007) 1.69
Transcriptional expression of genes involved in cell invasion and migration by normal and tumoral trophoblast cells. J Clin Endocrinol Metab (2002) 1.60
Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials (2009) 1.59
Physico-chemical stability of colloidal lipid particles. Biomaterials (2003) 1.44
Active targeting of brain tumors using nanocarriers. Biomaterials (2007) 1.42
Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood (2006) 1.35
Structure and function of a mitochondrial late embryogenesis abundant protein are revealed by desiccation. Plant Cell (2007) 1.34
Melanin is an essential component for the integrity of the cell wall of Aspergillus fumigatus conidia. BMC Microbiol (2009) 1.34
A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res (2002) 1.22
Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol Ther (2003) 1.15
Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials (2006) 1.12
Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond) (2010) 1.10
Adult cell therapy for brain neuronal damages and the role of tissue engineering. Biomaterials (2009) 1.08
Perfusional deficit and the dynamics of cerebral edemas in experimental traumatic brain injury using perfusion and diffusion-weighted magnetic resonance imaging. J Neurotrauma (2007) 1.04
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Biomaterials (2009) 1.02
The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells. PLoS One (2011) 1.02
Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials (2010) 1.01
Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol (2011) 1.00
Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments. Biomaterials (2007) 1.00
Distribution of lipid nanocapsules in different cochlear cell populations after round window membrane permeation. J Biomed Mater Res B Appl Biomater (2008) 1.00
High-resolution array comparative genomic hybridization analysis of human bronchial and salivary adenoid cystic carcinoma. Lab Invest (2008) 0.99
A new mathematical model quantifying drug release from bioerodible microparticles using Monte Carlo simulations. Pharm Res (2002) 0.99
The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. Nanomedicine (Lond) (2010) 0.99
Biological consequences of petite mutations in Candida glabrata. J Antimicrob Chemother (2005) 0.98
Nano-emulsions and nanocapsules by the PIT method: an investigation on the role of the temperature cycling on the emulsion phase inversion. Int J Pharm (2007) 0.98
Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocr Relat Cancer (2010) 0.97
Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death. J Immunol (2007) 0.95
A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials (2013) 0.95
Intravitreous injection of PLGA microspheres encapsulating GDNF promotes the survival of photoreceptors in the rd1/rd1 mouse. Mol Vis (2005) 0.95
The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials (2010) 0.92
Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur J Pharm Biopharm (2009) 0.92
Non-viral nanosystems for systemic siRNA delivery. Pharmacol Res (2009) 0.91
Influence of size, surface coating and fine chemical composition on the in vitro reactivity and in vivo biodistribution of lipid nanocapsules versus lipid nanoemulsions in cancer models. Nanomedicine (2012) 0.90
Anti-cancer drug diffusion within living rat brain tissue: an experimental study using [3H](6)-5-fluorouracil-loaded PLGA microspheres. Eur J Pharm Biopharm (2002) 0.90
Strategies for drug delivery to the human inner ear by multifunctional nanoparticles. Nanomedicine (Lond) (2011) 0.90
Tumor transfection after systemic injection of DNA lipid nanocapsules. Biomaterials (2010) 0.90
Reversible protein precipitation to ensure stability during encapsulation within PLGA microspheres. Eur J Pharm Biopharm (2008) 0.90
Brain targeting using novel lipid nanovectors. J Control Release (2007) 0.90
The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials (2010) 0.90
Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery (2005) 0.89
Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes. J Control Release (2004) 0.89
The encapsulation of DNA molecules within biomimetic lipid nanocapsules. Biomaterials (2009) 0.89
In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy. J Neurooncol (2009) 0.89
Drug delivery into the brain using poly(lactide-co-glycolide) microspheres. Expert Opin Drug Deliv (2005) 0.88
New lipid nanocapsules exhibit sustained release properties for amiodarone. J Control Release (2002) 0.88
Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm Res (2011) 0.88
Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice. Pharm Res (2010) 0.87
Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles. Biomaterials (2011) 0.87
Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interface. Electrophoresis (2005) 0.86
Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. Eur J Pharm Biopharm (2011) 0.86
Dynamics of cerebral edema and the apparent diffusion coefficient of water changes in patients with severe traumatic brain injury. A prospective MRI study. Eur Radiol (2006) 0.86
99mTc/188Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: formulation and biodistribution. Eur J Nucl Med Mol Imaging (2006) 0.86
Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications. Mol Pharm (2012) 0.86
Inner ear biocompatibility of lipid nanocapsules after round window membrane application. Int J Pharm (2010) 0.86
Surveillance of intestinal colonization and of infection by vancomycin-resistant enterococci in hospitalized cancer patients. Clin Microbiol Infect (1996) 0.85
Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment. Int J Pharm (2004) 0.85
A new tool to ensure the fluorescent dye labeling stability of nanocarriers: a real challenge for fluorescence imaging. J Control Release (2013) 0.85
Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. Int J Pharm (2010) 0.85
Pegylated nanocapsules produced by an organic solvent-free method: Evaluation of their stealth properties. Pharm Res (2006) 0.85
Active targeting strategies for anticancer drug nanocarriers. Curr Drug Deliv (2012) 0.84
Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. Int J Pharm (2011) 0.84
Striatal tyrosine hydroxylase immunoreactive neurons are induced by L-dihydroxyphenylalanine and nerve growth factor treatment in 6-hydroxydopamine lesioned rats. Neurosci Lett (2004) 0.83
188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma. Nucl Med Commun (2004) 0.83
The influence of lipid nanocapsule composition on their size distribution. Eur J Pharm Sci (2003) 0.83
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study. Int J Nanomedicine (2011) 0.83
Potential novel drug carriers for inner ear treatment: hyperbranched polylysine and lipid nanocapsules. Nanomedicine (Lond) (2009) 0.83
Novel metal-based anticancer drugs: a new challenge in drug delivery. Curr Opin Pharmacol (2012) 0.83
Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations. Int J Cancer (2006) 0.83